Chimerix INC: AR & d for smallpox antiviral
Active Definitive Contract Awarded Last action
- Contract number
- 75A50122C00047
- Awardee
-
Emergent Biodefense Operations Lansing LLC UEI JLLWGQX6LNA5
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $213,770,068
Award facts
- Opportunity
-
- Smallpox Antiviral Pre-Solicitation · 75A50122R00012 · Posted Mar 24, 2021
- Contract value 33% obligated
-
- $213,770,068.00 Current, with exercised options
- $649,849,467.00 Potential, with all options
- Completion date 42% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ15 General Science & Technology R&D Svcs; General Science & Technology; R&D Facilities & Maj Equip
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27713, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $2,360,280 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $17,104,200 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $67,400,676 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Novation Agreement | $0 | |
| Other Administrative Action | $0 | |
| Original award | $126,904,912 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Emergent Biodefense Operations Lansing LLC for research and development and procurement of smallpox antiviral oral suspension treatment courses on August 29, 2022, with a ceiling value of $649.8 million.
This modification exercises and fully funds optional CLIN 0005B for the procurement of 4,896 oral suspension treatment courses in the amount of $2.36 million, and extends the period of performance through August 28, 2031, with ultimate contract completion on August 24, 2032. Place of performance is Durham, NC. The originating sources-sought notice, posted March 24, 2021, sought information regarding development and manufacture of FDA-approved smallpox antiviral drugs with alternative mechanisms of action to TPOXX, requiring respondents to have an NDA or BLA submitted to and acknowledged by the FDA with a confirmed PDUFA date, and demonstrating manufacturing capacity and ability to fulfill post-marketing requirements. The contract is firm fixed price with no set-aside designation.
Quick answers
Who was awarded contract 75A50122C00047?
75A50122C00047 was awarded to Emergent Biodefense Operations Lansing LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on August 29, 2022.
How much is contract 75A50122C00047 worth?
The government has obligated $213,770,068 on 75A50122C00047. Its potential value, with all options, is $649,849,467.
Was contract 75A50122C00047 competed?
The extent of competition for 75A50122C00047 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award